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A B S T R A C T
Objectives: To inform health-technology assessments of new adjuvant treatments, we describe treatment patterns
in patients with complete resection of stage IB-IIIA non-small cell lung cancer (NSCLC) in France, Germany, and
the United Kingdom (UK).
Materials and methods: Data were collected via medical record abstraction. Patients were aged ≥18 years with
completely resected stage IB-IIIA NSCLC, diagnosed between 01 January 2009 and 31 December 2011. Median
follow-up was 26 months. Adjuvant treatment patterns and clinical outcomes were summarized descriptively.
Results: Among the 831 patients studied, 239 (29%) had stage IB disease, 179 (22%) had stage IIA disease, 165
(20%) had stage IIB disease, and 248 (30%) had stage IIIA disease. Adjuvant systemic therapy was received by
402 patients (48.4%), (France, 61.8%; Germany, 51.9%; UK, 33.4%). Use of adjuvant therapy increased with
increasing stage of disease. Cisplatin/vinorelbine and carboplatin/vinorelbine were the most frequently
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prescribed adjuvant regimens. Median disease-free survival was 48.0 months (95% conﬁdence interval [CI]
42.3–not estimable); the 25th percentile was 13.2 months (95% CI, 11.0–15.3). 204 patients (24%) died during
the follow-up period. The median overall survival was not reached, the 25th percentile was 31.2 months (95% CI
26.8–36.0 months). 272 patients (33%) had disease recurrence during the follow-up period. For 86 of those
patients, the ﬁrst recurrence was local or regional with no distant metastasis and 14 had further progression to
metastatic disease during the follow-up time. For the other 186 patients, the ﬁrst recurrence involved distant
metastases. A total of 200 patients had metastatic disease at any time during study follow-up.
Conclusions: Less than half the patients with stage IB-IIIA NSCLC in this observational study received adjuvant
systemic therapy. A high rate of ﬁrst recurrence with distant metastatic disease was observed, emphasising the
need for more eﬀective systemic adjuvant therapies in this population.
1. Introduction
Approximately one-third of cases of non-small cell lung cancer
(NSCLC) are diagnosed during early stages of the disease and are
therefore eligible for surgical resection with curative intent [1]. During
surgery, lymph nodes are removed and evaluated histologically. If
lymph node metastases are present (and there are no distant metas-
tases), the patient is classiﬁed as having stage II or III disease [2].
Adjuvant chemotherapy in early-stage NSCLC is recommended de-
pending on performance status and age but the extent of its use and the
agents and combinations used in routine practice are not well docu-
mented. Current adjuvant treatments for patients with complete re-
section of stage IB-IIIA NSCLC have limited eﬃcacy and substantial
toxicity [3,4]. There is a clinical need for more eﬃcacious and tolerable
therapies in the adjuvant setting, and such interventions are in devel-
opment [3]. To inform reimbursement bodies and cost-eﬀectiveness
evaluations on these upcoming interventions, health-technology as-
sessment agencies will require high-quality data describing current
treatment patterns. To our knowledge, few such studies have been
conducted in this population.
This observational study aimed primarily at identifying and quan-
tifying the treatment patterns of patients with complete resection of
stage IB-IIIA NSCLC in France, Germany, and the United Kingdom (UK).
As a second objective, the study aimed at evaluating the disease re-
currence and progression for the same patients.
The cost aspects of this study are reported in a back-to-back
manuscript in this issue [12].
2. Methods
This retrospective observational study (ClinicalTrials.gov identiﬁer:
NCT01772225) was conducted among patients with complete resection
of stage IB-IIIA NSCLC who were managed by oncologists, pulmonol-
ogists, and thoracic surgeons. Candidate study sites were identiﬁed
using a list of clinical centres known to treat patients with NSCLC for
each country. Following an in-depth feasibility enquiry with nine sites
(three in each country), study centres were selected with a view to the
inclusion of patients and physicians that are representative of the
country as a whole with respect to care received (adjuvant and post-
progression, including interferon use), while recognising the practi-
calities of recruiting a suﬃcient sample for the study. Eligible patients
were≥18 years old with completely resected stage IB-IIIA NSCLC (7th
Edition of TNM classiﬁcation for Lung Cancer Staging) diagnosed be-
tween 01 January 2009 and 31 December 2011, had no other cancer
treated during follow-up, and had not participated in clinical trials of
novel adjuvant therapy. Patients were enrolled through clinical centres
using a systematic method for patient sampling to minimise the po-
tential for selection bias.
Study centres in France, Germany, and the UK screened patients for
eligibility using medical records of patients who were either living or
deceased. Data were extracted at the clinical site via an electronic case
report form developed for this study. Data included patient demo-
graphic and disease characteristics, secondary and supportive care
received, type of adjuvant treatments administered, and resource uti-
lisation. Data on disease recurrence and progression were also as-
sembled for analyses centring on disease-free survival (DFS), distant-
metastases-free survival (DMFS), and overall survival (OS).
This study was approved by the following ethics committees:
• UK: National Research Ethics Service Committee Yorkshire and the
Humber-Sheﬃeld; date of approval: 12 December 2012
• Germany: Landesärztekammer Hessen; date of approval: 13
December 2012
• France: Comité Consultatif sur le Traitement de l’Information en
matière de Recherche dans le domaine de la Santé (CCTIRS); date of
approval: 19 December 2012
• France: Commission Nationale de l’Informatique et des Libertés
(CNIL); date of approval: 25 February 2013
As per the study data management plan, data were omitted from
patients whose medical record abstractions were performed in-
completely, patients for whom implausible disease progression or
treatment dates were reported, patients whose abstracted data were
subject to protocol violations, and patients who opted out of the med-
ical record abstraction.
The analysis was descriptive and no hypotheses were formally
tested. Results were generated separately for each country and for all
countries combined, but no statistical comparisons for results by
country were conducted. For time-to-event outcomes (DFS, DMFS, and
OS), the number of patients with events and the number censored are
presented. Median and 25th percentile times and associated 95% con-
ﬁdence intervals (CIs) were estimated, where possible, using the
Kaplan-Meier method for each country and for all countries together.
Kaplan-Meier survival curves by country were also plotted for each
time-to-event outcome.
Edit and logic checks based on the data collected (e.g., cross-refer-
encing between questions) were conducted and queries resolved, where
possible.
3. Results
3.1. Study sites and patient participation
Thirty-nine study sites participated in the study (France, 14;
Germany, 11; UK, 14); 20 sites (53%) were specialist cancer sites, 19
(50%) were teaching hospitals, 9 (24%) were tertiary referral sites, and
4 (11%) were other types of facilities (categories not mutually ex-
clusive). One site did not report facility type. Most sites (32 [84%])
reported treating more than 40 NSCLC patients monthly.
The study sites entered data on 868 patients, out of which 831
(95.7%) had suﬃcient data to be eligible for analysis (France, 251;
Germany, 287; UK, 293). The median follow-up period for all patients
was 26 months (France, 30 months; Germany, 24 months; UK, 25
months).
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3.2. Patient characteristics
Of 831 patients, 62% (513/831) were male, although the proportion
ranged from 70.9% in France to 61.0% in Germany and 54.6% in the
UK. Overall, 67% (557/831) were aged>65 years at diagnosis and
there were 20–30% of patients in each disease stage. Adenocarcinomas
were the most prevalent (53%) followed by squamous cell carcinoma
(38%), large cell tumors (2%) and other/unspeciﬁed (6%). Overall,
7.7% of patients had participated in clinical trials of post-recurrence
treatment (Table 1). A similar proportion of patients were current
smokers across the three countries (Table 2).
3.3. Adjuvant systemic therapy
Overall, 402 patients (48.4%) received adjuvant systemic therapy
(61.8% in France, 51.9% in Germany, and 33.4% in the UK). The use of
adjuvant therapy increased with advancing disease stage in all three
countries (Table 3).
Overall cisplatin/vinorelbine, the most frequently prescribed ad-
juvant regimen in all three countries, was given to 258 patients (64.2%
of those who received any adjuvant systemic therapy overall) with high
heterogeneity between France, Germany, and the UK. Carboplatin/vi-
norelbine was given to 39 patients (9.7% of those who received any
adjuvant systemic therapy overall). Cisplatin/gemcitabine was given to
19 patients (4.7% of those given any adjuvant systemic therapy).
Overall, no other adjuvant chemotherapy regimen was given to more
than 4% of all patients receiving adjuvant chemotherapy. If we consider
data per country, the only other regimens given to more than 4% of
patients receiving adjuvant chemotherapy in any country were carbo-
platin/paclitaxel (given to 8.4% of patients receiving adjuvant che-
motherapy in France), carboplatin/pemetrexed (given to 6.0% of pa-
tients receiving adjuvant chemotherapy in Germany), cisplatin/
pemetrexed (given to 5.2% and 4.7% of patients receiving adjuvant
chemotherapy in France and Germany, respectively), and cisplatin
alone (given to 5.1% of patients receiving adjuvant chemotherapy in
the UK) (see Supplemental Table 1).
The median number of planned and administered cycles was four
for cisplatin/vinorelbine and carboplatin/vinorelbine, and 3.5 for cis-
platin/gemcitabine. A majority of patients treated with the three most
common adjuvant chemotherapy regimens completed their planned
course of treatment for both drugs (cisplatin [62.1%]/vinorelbine
[66.0%]; carboplatin [64.1%]/vinorelbine [59.0%]; cisplatin [57.9%]/
gemcitabine [57.9%]). The proportion of patients receiving adjuvant
chemotherapy exclusively in the outpatient setting was greater for
those receiving carboplatin/vinorelbine (72%) than for those receiving
cisplatin/vinorelbine (55%) or cisplatin/gemcitabine (53%).
Of the 429 (51.6%) patients across the three countries who did not
receive adjuvant systemic therapy, reasons included treatment being
declined by the patient (12.6%), comorbidities (11.9%), complication
or delay in recovery from surgery (8.4%), and poor performance status
(7%).
3.4. Survival and disease recurrence
Overall, 272 patients (33%) had disease recurrence during the ob-
served follow-up period; however, the results diﬀered by country with
disease recurrence ranging from 26% observed in the UK sample to 43%
in the French sample (Table 4). For 86 patients (10% of the total; 32%
of those with recurrence), the ﬁrst recurrence was local or regional with
no distant metastasis. For the other 186 patients (22% of the total; 68%
of those with recurrence), the ﬁrst recurrence involved distant metas-
tases (60 of whom also had concomitant local or regional recurrence).
Among the 86 patients with only local disease at ﬁrst recurrence, 14
progressed to metastatic disease during the follow-up time observed, so
a total of 200 patients had metastatic disease at any time during study
follow-up. Heterogeneity was observed across the countries with 11.5%
observed in the German sample ranging to 22.7% in the UK for patients
with further progression to distant metastases. The most common sites
of metastasis (not mutually exclusive) were brain (82 patients; 41%),
lung (65 patients; 33%), bone (47 patients; 24%), and liver (26 patients;
13%).
The median OS was not reached during the follow-up time available
for analysis. The 25th percentile of estimated OS was 31.2 months (95%
conﬁdence interval [CI] 26.8–36.0 months). Overall, 204 patients
(24%) were reported to have died; however, the survival analysis in-
cluded only 201 of these 204 deaths as date of death was not reported
for 3 patients (Table 4).
Median DFS was 48.0 months (95% CI, 42.3 months–not estimable);
median DFS was 38.5 months in France (95% CI, 27.4–non estimable
[NE]), 48.0 months in Germany (95% CI, 48.0 months–NE), and NE in
the UK (95% CI, 42.3-NE) (Fig. 1). First quartile DFS appears to be
substantially longer for patients with stage IB disease than for those
with IIA, IIB, or IIIA disease (Table 5).
Among the 86 patients who had local or regional recurrence without
metastases, 43 (50%) received systemic treatment. Heterogeneity was
observed across countries with 66% of the French patients receiving
systemic treatment, 42% of the German patients, and 32% of the UK
patients. Among the 200 patients who experienced distant metastatic
disease (whether it represented their ﬁrst recurrence or progression
from a local or regional recurrence), 97 (49%) received systemic
Table 1
Patient characteristics at inclusion.
Characteristic France
(N=251)
n (%)
Germany
(N=287)
n (%)
United
Kingdom
(N=293)
n (%)
Overall
(N= 831)
n (%)
Age in years
≤ 60 110 (43.8) 98 (34.1) 66 (22.5) 274 (33.0)
61–70 90 (35.9) 109 (38.0) 109 (37.2) 308 (37.1)
≥ 71 51 (20.3) 80 (27.9) 118 (40.3) 249 (30.0)
Male 178 (70.9) 175 (61.0) 160 (54.6) 513 (61.7)
Carcinoma type
Adenocarcinoma or
bronchioloalveolar
151 (60.2) 152 (53.0) 141 (48.1) 444 (53.4)
Squamous cell 78 (31.1) 111 (38.7) 125 (42.7) 314 (37.8)
Large cell 8 (3.2) 7 (2.4) 5 (1.7) 20 (2.4)
Other or unspeciﬁed
histologya
14 (5.6) 17 (5.9) 22 (7.5) 53 (6.4)
Pathologic disease stage
IB 58 (23.1) 70 (24.4) 111 (37.9) 239 (28.8)
IIA 39 (15.6) 57 (19.9) 83 (28.3) 179 (21.5)
IIB 46 (18.3) 64 (22.3) 55 (18.8) 165 (19.9)
IIIA 108 (43.0) 96 (33.4) 44 (15.0) 248 (29.8)
ECOG performance statusb
0 or 1 114 (98.3) 114 (95.8) 188 (94.0) 416 (95.6)
Karnofsky performance statusc
80% to 100% 0 47 (94.0) 0 47 (94.0)
Systematic lymph node
dissection
241 (96.0) 259 (90.2) 98 (33.4) 598 (72.0)
Comorbidities (categories not mutually exclusive)
Cardiovascular
disease
84 (33.5) 160 (55.7) 89 (30.4) 333 (40.1)
Chronic obstructive
pulmonary disease
or asthma
50 (19.9) 89 (31.0) 76 (25.9) 215 (25.9)
History of cancers
other than NSCLC
35 (13.9) 27 (9.4) 29 (9.9) 91 (11.0)
Other or no data
available
192 (76.5) 210 (73.2) 209 (71.3) 611 (73.5)
ECOG=Eastern Cooperative Oncology Group; NSCLC=non-small cell lung
cancer.
a Other carcinoma type is represented by adenosquamous carcinoma, carci-
noma with pleomorphic sarcomatoid or sarcomatous elements, NSCLC not
speciﬁed, or other.
b Reported for 435 patients. At time of surgical resection.
c Reported for 50 patients.
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treatment. The most commonly prescribed agents to treat distant me-
tastatic disease were pemetrexed (41 patients) and carboplatin (40
patients).
4. Discussion
Age and sex distributions of patients in this study are generally
consistent with those of the NSCLC population who have undergone
complete surgical resection and who are candidates for adjuvant
therapy [5]; approximately half were older than 65 years and a ma-
jority were male (61.7% overall). Another characteristic of NSCLC po-
pulations is the reported smoking rate (current or past) of over 80%.
The proportion of current smokers was the highest in Germany (28.6%)
and the lowest in France (20.7%). Because smoking behaviour is self-
reported, smoking is a known cause of lung cancer [6], and there is a
social stigma associated with smoking; these quantitative ﬁndings
should be interpreted cautiously.
Adenocarcinoma was the most common histology in the study
sample (52.7%), followed by squamous cell carcinoma (37.8%). This is
consistent with an increasing proportion of patients having adeno-
carcinoma histology and a decreasing proportion having squamous cell
histology over recent years, which has been observed in studies of
NSCLC in several European countries, including the UK [7] and France
[8]. Performance status, among approximately half of the patients for
whom it was reported, was generally good (ECOG 0 or 1), which is
consistent with the selection of patients for surgical resection, ac-
cording to published guidelines [9,10].
The most frequent stage of disease in the study population was IIIA
(29.8%), followed by IB (28.8%), IIA (21.5%), and IIB (19.9%).
However, stage distribution varied markedly by country. In France, the
proportion of patients with stage IIIA was higher (43.0%) than in
Germany (33.4%) or the UK (15.0%); the proportion of patients with
Table 2
Smoking status.
Smoking Status France (N=251)a
n (%)
Germany (N=287)a
n (%)
United Kingdom (N=293)a
n (%)
Overall (N=831)a
n (%)
Never smoked (less than 100 cigarettes in their life) 32 (12.7) 28 (9.8) 20 (6.8) 80 (9.6)
Permanently stopped smoking before lung cancer was
suspected
108 (43.0) 90 (31.4) 140 (47.8) 338 (40.7)
Permanently stopped smoking after lung cancer was suspected
and before resection surgery
38 (15.1) 30 (10.5) 31 (10.6) 99 (11.9)
Permanently stopped smoking after resection surgery 10 (4.0) 18 (6.3) 9 (3.1) 37 (4.5)
Current smoker 52 (20.7) 82 (28.6) 69 (23.5) 203 (24.4)
Data not available 11 (4.4) 39 (13.6) 24 (8.2) 74 (8.9)
a N: Denominator for percentage calculation is number of patients for whom smoking status was reported.
Table 3
Percentages of patients receiving adjuvant therapy, by stage.
Variable France (N=251)a n (%) Germany (N=287)a n (%) United Kingdom (N=293)a n (%) Overall (N= 831)a n (%)
Patients receiving adjuvant chemotherapy
None 96 (38.2) 138 (48.1) 195 (66.6) 429 (51.6)
Received adjuvant chemotherapy 155 (61.8) 149 (51.9) 98 (33.4) 402 (48.4)
Stage IBb 10/58 (17.2) 12/70 (17.1) 14/111 (12.6) 36/239 (15.1)
Stage IIAb 22/39 (56.4) 34/57 (59.6) 37/83 (44.6) 93/179 (52.0)
Stage IIBb 32/46 (69.6) 39/64 (60.9) 25/55 (45.5) 96/165 (58.2)
Stage IIIAb 91/108 (84.3) 64/96 (66.7) 22/44 (50.0) 177/248 (71.4)
a N: Denominator for percentage calculation is the number of patients for whom data were recorded for the respective question.
b The number of patients receiving adjuvant chemotherapy in each country was used as the denominator.
Table 4
Non-small cell lung cancer progression and death from the medical record abstraction.
Variable France (N=251)
n (%)
Germany (N=287)
n (%)
United Kingdom (N=293)
n (%)
Overall (N= 831)
n (%)
Patients with recurrence 108 (43.0) 89 (31.0) 75 (25.6) 272 (32.7)
Local or regional recurrence only 38 (35.2) 26 (29.2) 22 (29.3) 86 (31.6)
Distant metastases with local or regional recurrence 21 (19.4) 21 (23.6) 18 (24) 60 (22.1)
Distant metastases without local or regional recurrence 49 (45.4) 42 (47.2) 35 (46.7) 126 (46.3)
Further progression to distant metastases
(for patients with local/regional recurrence only)
6 (15.8) 3 (11.5) 5 (22.7) 14 (16.3)
Patients deceased 67 (26.7) 84 (29.3) 87 (29.7) 238 (28.6)
Death due to NSCLC or NSCLC complications (or NSCLC could
not be ruled out as cause)
55 (82.1) 34 (40.5) 44 (50.6) 133 (55.9)
Death due to other cause(s) 8 (11.9) 7 (8.3) 15 (17.2) 30 (12.6)
Death due to unknown cause 3 (4.5) 13 (15.5) 25 (28.7) 41 (17.2)
Data not available 1 (1.5) 30 (35.7) 3 (3.4) 34 (14.3)
Setting of death 66 54 84 204
At home 10 (15.2) 3 (5.6) 10 (11.9) 23 (11.3)
In hospital (private hospital in France and Germany) 4 (6.1) 0 32 (38.1) 36 (17.6)
In public hospital (for France and Germany only) 42 (63.6) 23 (42.6) 0 65 (31.9)
In a hospice (for Germany and UK only) 0 1 (1.9) 8 (9.5) 9 (4.4)
Data not available 10 (15.2) 27 (50.0) 34 (40.5) 71 (34.8)
NSCLC=non-small cell lung cancer.
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stage IB was the highest in the UK (37.9%), intermediate in Germany
(24.4%), and the lowest in France (23.1%). The less frequent use of
systematic lymph node dissection in the UK (33.4%, compared with
96.0% in France and 90.2% in Germany) may have resulted in some
“understaging” of the patients in the UK. Possible diﬀerential use of
positron emission computed tomography could be another reason
contributing to this diﬀerence. Alternatively, proportionately more
patients with higher-stage disease (IIB and IIIA) may have been referred
for deﬁnitive radiation therapy in the UK than other countries, rather
than being treated primarily with surgery; however, we did not collect
the information that would be needed to directly assess this assumption.
Adjuvant cisplatin-based doublet chemotherapy is recommended
after surgery for stage II and III disease based on 23 randomised trials
published from 1992 to 2005 and ﬁve meta-analyses [5]. The European
Society for Medical Oncology (ESMO) Consensus guidelines re-
commends a two-drug combination with cisplatin for patients with
NSCLC who are to receive adjuvant chemotherapy [11]. Eﬃcacy in
stage IB remains controversial; data suggest a survival beneﬁt only in
patients with tumours larger than 4 or 5 cm in diameter [11]. The
National Institute for Health and Care Excellence (NICE) (2011)
Fig. 1. Kaplan-Meier survival curves for disease-free survival, by country UK: United Kingdom.
Table 5
Time to event outcomes (time from surgical resection), by stage.
Variable Stage I B (N=239)
n (%)
Stage II A (N=179)
n (%)
Stage II B (N=165)
n (%)
Stage III A (N=248)
n (%)
Overall (N= 831)
n (%)
Disease-free survival (DFS)
Total patients 239 179 165 248 831
Disease recurrence or death 71
(29.7)
68
(38.0)
73
(44.2)
120 (48.4) 332 (40.0)
Censored 168 (70.3) 111 (62.0) 92
(55.8)
128 (51.6) 499 (60.0)
25th percentile of DFS, months (95% CI) 23.7
(18.6, 33.9)
11.9
(9.7, 16.8)
8.7
(6.8, 13.2)
10.2
(8.5, 13.5)
13.2
(11.0, 15.3)
Median DFS, months (95% CI) NE
(NE, NE)
42.3
(42.3, NE)
38.5
(25.2, NE)
28.5
(23.4, NE)
48.0
(42.3, NE)
Min, max 0.2, 50.4 0.1, 49.6 0.4, 51.4 0.4, 50.4 0.1, 51.4
Distant metastasis-free survival (DMFS)
Total patients 238 179 165 248 830
Distant metastasis or death 59
(24.8)
63
(35.2)
63
(38.2)
99
(39.9)
284 (34.2)
Censored 179 (75.2) 116 (64.8) 102 (61.8) 149 (60.1) 546 (65.8)
25th percentile of DMFS, months (95% CI) 31.6
(20.0, NE)
15.8
(11.3, 23.2)
15.2
(7.7, 21.2)
14.8
(10.6, 17.7)
17.7
(15.2, 19.9)
Median DMFS, months (95% CI) NE
(NE, NE)
42.3
(41.7, NE)
48.0
(35.1, NE)
47.4
(30.2, NE)
NE
(48.0, NE)
Min, max 0.2, 50.4 0.1, 49.6 0.4, 51.4 0.4, 50.4 0.1, 51.4
Overall survival (OS)
Total patients 237 179 165 247 828
Death 34
(14.3)
54
(30.2)
47
(28.5)
66
(26.7)
201 (24.3)
Censored 203 (85.7) 125 (69.8) 118 (71.5) 181 (73.3) 627 (75.7)
25th percentile of OS, months (95% CI) NE
(NE, NE)
25.1
(17.8, 32.4)
22.1
(16.0, 38.6)
28.2
(20.4, 35.2)
31.2
(26.8, 36.0)
Median OS, months (95% CI) NE
(NE, NE)
43.2
(40.2, NE)
NE
(NE, NE)
NE
(NE, NE)
NE
(NE, NE)
Min, max 0.2, 50.4 0.1, 50.2 0.4, 51.4 0.4, 50.4 0.1, 51.4
CI= conﬁdence interval; NE=non estimable.
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recommended oﬀering postoperative adjuvant chemotherapy to pa-
tients with completely resected NSCLC, good performance status, and
T1–3 N1–2 M0 disease; the same should be considered for patients with
T2–3 N0 M0 NSCLC and tumours greater than 4 cm in diameter.
In our study, more than 40% of the patients with stage II and 28.6%
of patients with stage IIIA did not receive adjuvant therapy despite
recommendation from the guidelines. Among those patients receiving
adjuvant chemotherapy, the observed type adjuvant chemotherapy in
our study is generally consistent with published guidelines [9,10]. The
proportion of patients given adjuvant chemotherapy was relatively low
among those with stage IB disease (15.1%). The overall proportions of
patients with higher stages given adjuvant chemotherapy (stage IIA,
52.0%; stage IIB, 58.2%; stage IIIA, 71.4%) indicate that its use is
considerably greater within the patient groups for whom evidence more
consistently shows a survival beneﬁt. The same trends were observed
within each country, although, stage for stage, the use of adjuvant
chemotherapy was the greatest in France, intermediate in Germany,
and the lowest in the UK. Other common reasons for not using adjuvant
chemotherapy were patient declination and presence of comorbidities.
The predominant use of cisplatin/vinorelbine in this study (ad-
ministered to 66.5% of patients given adjuvant chemotherapy in
France, 55.7% in Germany, and 73.5% in the UK) is consistent with
published clinical trials of adjuvant chemotherapy in patients with
NSCLC [9]. It is not surprising that carboplatin/vinorelbine was the
second most frequently prescribed adjuvant chemotherapy regimen,
since carboplatin and cisplatin are closely related in terms of their
chemical composition and pharmacologic activities, and carboplatin is
frequently substituted for cisplatin in standard chemotherapy regimens,
particularly in patients with impaired renal function.
Major clinical outcomes in the adjuvant treatment setting (DFS,
DMFS, and OS) are time-dependent. Because the present study was
primarily designed to assess recent patterns of care and costs among
patients eligible to receive adjuvant chemotherapy, the eligible period
of diagnosis of NSCLC was restricted and the follow-up time available
for analysis was consequently limited. Therefore, information was not
complete enough to estimate median OS (or even median DFS in all
countries). This limitation and other diﬀerences in study populations
should be considered while evaluating these results in the context of
clinical trials of adjuvant chemotherapy, where typically results are not
reported until follow-up is more mature.
Although the OS experience by stage cannot be directly compared
with previously published survival estimates [5] and patients did not all
receive adjuvant chemotherapy (proportions varied by stage), several
observations can be made about the present study. First, OS estimates
by stage indicate that survival proportions at the median overall follow-
up time (26 months) for each stage are greater than the 5-year OS es-
timates published by Lim et al. [5].). DFS data should be interpreted
with caution as they are expected to be inﬂuenced by follow-up patterns
and recording of disease recurrence, and these are expected to diﬀer
from those used in clinical trials and also to vary among countries.
Therefore, it is not possible to draw any conclusions about diﬀerences
in DFS among countries. Second, there is an apparently “tighter” dis-
tribution of OS at the median time of follow-up (26 months) among
patients with stages IIA, IIB, and IIIA in the LuCaBIS population than
one might expect based on the spread of 5-year survival estimates
published by Lim et al. [5]. Without additional subgroup analyses, it is
not possible to determine the extent to which this is related to the
observation that the proportion of patients receiving adjuvant che-
motherapy in the LuCaBIS population increased by increasing stage,
thus perhaps obscuring diﬀerences that might be observed in a popu-
lation of patients who had all received adjuvant chemotherapy.
There were several study limitations. The study used a quasi-
random sampling method for the selection of patients within study
sites. Sites were selected to achieve variation in geographic location,
size, and type, but study data may not be perfectly representative of all
sites and physicians treating patients with stage IB-IIIA NSCLC across
each country. As with all studies that rely on existing medical records,
availability of information varied by practice and country and reﬂects
diﬀerences in practice patterns, recording practices, and medical
norms. External validation of medical record data was not conducted.
Nevertheless, we believe that this study makes a useful contribution to
the evidence base required for clinical and health economic decision
making.
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